Abstract
Introduction: Data on basal hypothalamo-pituitary-adrenomedullary (HPA) function over controlled treatment trials with serotonergic drugs in anxiety disorders are still rare. Methods: 29 patients with panic disorder participating in a 10 week randomized, controlled trial (paroxetine vs. placebo with exercise or relaxation; N=60) collected urine for cortisol excretion over 3 consecutive nights before start and before termination of the treatment episode. Urinary cortisol was measured by radioimmunoassay. Efficacy measures were the Clinical Global Impression Scale (CGI) and the Panic and Agoraphobia Scale (P). 83% were female (p < .05 vs. males). 55% received additional aerobic exercise, and 45% relaxation. 55% received paroxetine treatment, and 45% placebo. Significantly fewer males received placebo treatment (p < .05). Results: All subjects improved significantly. Cortisol excretion did not differ between treatment groups or at pre-/post measurements. Females showed a significantly higher variability of cortisol excretion compared to males, at pre-(p < .005) and post (p=.015) assessments. Males displayed a trend to lower basal HPA function at end of treatment (p=.08). HPA variability after treatment showed a trend to be higher in the paroxetine (p=.052) -who clinically improved significantly better- compared to the placebo group. No relationship between HPA activity and treatment response or with exercise was detected. Discussion: HPA function shows significant gender differences, with females having a higher HPA function variability. Future studies on HPA function in treatment trials should address gender and medication effects.
Keywords: Panic disorder, cortisol, HPA axis, paroxetine, gender, antidepressants
Current Pharmaceutical Design
Title: Nocturnal Urinary Cortisol Excretion Over a Randomized Controlled Trial with Paroxetine vs. Placebo Combined with Relaxation Training or Aerobic Exercise in Panic Disorder
Volume: 14 Issue: 33
Author(s): D. Wedekind, A. Sprute, A. Broocks, G. Huther, K. Engel, P. Falkai and B. Bandelow
Affiliation:
Keywords: Panic disorder, cortisol, HPA axis, paroxetine, gender, antidepressants
Abstract: Introduction: Data on basal hypothalamo-pituitary-adrenomedullary (HPA) function over controlled treatment trials with serotonergic drugs in anxiety disorders are still rare. Methods: 29 patients with panic disorder participating in a 10 week randomized, controlled trial (paroxetine vs. placebo with exercise or relaxation; N=60) collected urine for cortisol excretion over 3 consecutive nights before start and before termination of the treatment episode. Urinary cortisol was measured by radioimmunoassay. Efficacy measures were the Clinical Global Impression Scale (CGI) and the Panic and Agoraphobia Scale (P). 83% were female (p < .05 vs. males). 55% received additional aerobic exercise, and 45% relaxation. 55% received paroxetine treatment, and 45% placebo. Significantly fewer males received placebo treatment (p < .05). Results: All subjects improved significantly. Cortisol excretion did not differ between treatment groups or at pre-/post measurements. Females showed a significantly higher variability of cortisol excretion compared to males, at pre-(p < .005) and post (p=.015) assessments. Males displayed a trend to lower basal HPA function at end of treatment (p=.08). HPA variability after treatment showed a trend to be higher in the paroxetine (p=.052) -who clinically improved significantly better- compared to the placebo group. No relationship between HPA activity and treatment response or with exercise was detected. Discussion: HPA function shows significant gender differences, with females having a higher HPA function variability. Future studies on HPA function in treatment trials should address gender and medication effects.
Export Options
About this article
Cite this article as:
Wedekind D., Sprute A., Broocks A., Huther G., Engel K., Falkai P. and Bandelow B., Nocturnal Urinary Cortisol Excretion Over a Randomized Controlled Trial with Paroxetine vs. Placebo Combined with Relaxation Training or Aerobic Exercise in Panic Disorder, Current Pharmaceutical Design 2008; 14 (33) . https://dx.doi.org/10.2174/138161208786848757
DOI https://dx.doi.org/10.2174/138161208786848757 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Mast Cell and Basophil Functions by Benzene Metabolites
Current Pharmaceutical Design Structure-Activity Relationships for Serotonin Transporter and Dopamine Receptor Selectivity
Medicinal Chemistry Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Puerarin: A Review on the Pharmacological Activity, Chemical Properties and Pharmacokinetics of Main Isoflavonoid
The Natural Products Journal Whole Brain Atrophy and Sample Size Estimate via Iterative Principal Component Analysis for Twelve-month Alzheimer's Disease Trials
Neuroscience and Biomedical Engineering (Discontinued) Motor Recovery after Chronic Spinal Cord Transection in Rats: A Proof-of-Concept Study Evaluating a Combined Strategy
CNS & Neurological Disorders - Drug Targets The Self-Reference Effect on Episodic Memory Recollection in Young and Older Adults and Alzheimer’s Disease
Current Alzheimer Research Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer
Current Pharmaceutical Biotechnology Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Current Alzheimer Research Renal COX-2, Cytokines and 20-HETE: Tubular and Vascular Mechanisms
Current Pharmaceutical Design Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Renin-Angiotensin-Aldosterone System and Migraine: A Systematic Review of Human Studies
Protein & Peptide Letters Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties
CNS & Neurological Disorders - Drug Targets Editorial [ Targeting Neurotrophic Factors, Their Receptors, and Signalling Pathways with Small Molecule Mimetics and Modulators to Achieve Neuroprotection and Regeneration Guest Editor: Stephen D. Skaper ]
CNS & Neurological Disorders - Drug Targets Ampelopsin Improves Cognitive Impairment in Alzheimer’s Disease and Effects of Inflammatory Cytokines and Oxidative Stress in the Hippocampus
Current Alzheimer Research Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine Somatic Treatments Excluding Psychopharmacology in Obsessive- Compulsive Disorder: A Review.
Reviews on Recent Clinical Trials